Inspyr Therapeutics Announces Research Collaboration with the National Institutes of Health

WESTLAKE VILLAGE, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) — Inspyr Therapeutics (OTCQB:NSPX), a clinical-stage biotechnology company, announced the initiation of a new investigator-sponsored preclinical study of its proprietary adenosine receptor modulator (ARM) based compounds. This preclinical study, led by Elizabeth Kang, M.D., of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), will evaluate these compounds for the prevention of graft versus host disease (GvHD), a potential side effect of allogeneic stem cell transplants.

“Our novel adenosine receptor agonists have demonstrated the ability to inhibit the inflammatory response in a previous preclinical study of GvHD,” said Ronald Shazer, M.D., Chief Medical Officer of Inspyr Therapeutics. “We are pleased that Dr. Kang and her colleagues at NIAID are moving this research forward to evaluate our adenosine receptor agonists’ potential in preventing GvHD. We look forward to having results from this new study and we are excited that this and other preclinical studies of compounds generated through our ARM technology platform are bringing our adenosine receptor modulators another step closer to clinical studies.”

About Graft versus Host Disease
Certain diseases and cancers can be treated effectively with stem cell transplants. Following allogeneic transplantation, some patients develop graft versus host disease, which occurs when the donor’s immune cells attack the body’s healthy cells. This disease can be acute or chronic, and cases range from those with mild symptoms to those ending in death.

About Inspyr Therapeutics
Inspyr Therapeutics, Inc. is an integrated biopharmaceutical company focused on the development of novel therapies to treat cancer, inflammation, and other serious diseases. Through a merger with Lewis and Clark Pharmaceuticals, Inc., Inspyr has a proprietary, industry-leading adenosine receptor modulator (ARM) technology platform and a broad pipeline of novel therapies. Inspyr’s pipeline includes Mipsagargin, a pro-drug that has completed a phase 2 clinical trial for the treatment of liver cancer, and the ARM preclinical programs consisting of A2A, A2B, and dual A2A/A2B receptor antagonists for the treatment of cancer and A2A agonists for the treatment of inflammatory and other serious diseases. The Company has fully-equipped, state-of-the-art organic and analytical chemistry laboratories located in Charlottesville, Virginia, where a team of chemists and toxicologists have expertise in chemical synthesis and analysis, non-clinical dose formulation, plasma concentration analysis, assay development, and toxicology. For additional information on Inspyr Therapeutics, visit

Inspyr’s Cautionary Statement Regarding Forward Looking Information
This communication may contain forward-looking statements. Investors are cautioned that statements in this document regarding potential applications of Inspyr’s technologies or the future prospects of the company constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights and the acceptance of Inspyr’s proposed therapies by the health community. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in Inspyr’s periodic reports filed with the Securities and Exchange Commission.

Inspyr Therapeutics Contact:
Lisa Cali